Stryker Co. (NYSE:SYK) Shares Purchased by Royal Fund Management LLC

Royal Fund Management LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,952 shares of the medical technology company’s stock after acquiring an additional 327 shares during the period. Royal Fund Management LLC’s holdings in Stryker were worth $2,381,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Kingswood Wealth Advisors LLC raised its position in shares of Stryker by 28.4% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 904 shares of the medical technology company’s stock valued at $247,000 after acquiring an additional 200 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in shares of Stryker by 3.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 177,831 shares of the medical technology company’s stock worth $48,596,000 after buying an additional 6,127 shares during the last quarter. Simon Quick Advisors LLC boosted its holdings in shares of Stryker by 11.5% in the 3rd quarter. Simon Quick Advisors LLC now owns 1,124 shares of the medical technology company’s stock valued at $307,000 after buying an additional 116 shares during the period. Stratos Wealth Partners LTD. grew its position in shares of Stryker by 8.5% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 15,672 shares of the medical technology company’s stock valued at $4,283,000 after buying an additional 1,230 shares during the last quarter. Finally, Stratos Wealth Advisors LLC raised its stake in Stryker by 5.0% during the third quarter. Stratos Wealth Advisors LLC now owns 3,790 shares of the medical technology company’s stock worth $1,036,000 after acquiring an additional 179 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a report on Wednesday. TD Cowen upped their price target on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Roth Mkm lifted their price objective on shares of Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler lifted their price target on Stryker from $375.00 to $380.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, BTIG Research upped their price objective on shares of Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $365.94.

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Trading Up 0.6 %

SYK traded up $1.82 during trading on Friday, reaching $328.45. The company had a trading volume of 1,589,424 shares, compared to its average volume of 1,415,127. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The firm’s 50-day simple moving average is $346.99 and its 200 day simple moving average is $317.29. The company has a market cap of $125.12 billion, a price-to-earnings ratio of 37.49, a PEG ratio of 2.56 and a beta of 0.91. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.97 and a current ratio of 1.71.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.10 billion. During the same period in the previous year, the company posted $2.14 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities research analysts anticipate that Stryker Co. will post 11.94 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were issued a $0.80 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.97%. Stryker’s dividend payout ratio is 36.53%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.